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Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder, and a major cause 
of infertility in women. An excessive amount of androgen hormones are produced by polycystic ovaries 
in PCOS with irregular menstruation and anovulation as result. The most common early symptoms are 
infertility, hirsutism and acne. Type 2 diabetes mellitus, metabolic syndrome, and possibly 
cardiovascular disease and endometrial carcinoma are all associated as lifelong implications with the 
diagnosis of PCOS. Medical treatment of PCOS should be tailored to the woman's symptoms and 
goals. In broad terms, treatment includes diet regulation, weight loss, oral contraceptives, clomiphene 
citrate and in vitro fertilization.  
Introduction:
Polycystic ovary syndrome (PCOS) is the most common cause of infertility in women (1). The major 
clinical features of polycystic ovary syndrome include menstrual dysfunction, anovulation and signs of 
hyperandrogenism. Women with PCOS often have a normal or slightly delayed onset of menarche, and 
in some women the irregularities in menstrual cycle develop when they gain weight. The menstrual 
irregularities that women with PCOS have are characterized by oligo- or amenorrhea with infrequent or 
absent ovulation leading to infertility (2). The clinical signs of hyperandrogenism are hirsutism with 
thick facial and/or body hair in a typically male pattern, acne, and in some cases male pattern hair loss.
I first got introduced to this syndrome by a friend of mine who told me about her symptoms and that 
she was diagnosed with PCOS at the age of 19. Little did I know about this complex syndrome before I 
sat down and researched about it on the internet the next day. I then realized that being diagnosed with 
this syndrome would make a huge impact on a young woman’s life. Since then, I have been curious to 
learn more about PCOS. What is PCOS? What are the main criteria to tell ascertain person that she has 
PCOS? What kind of clinically manifestations will a person with PCOS have? What is the main 
medical treatment for PCOS?
The aim of this study was to describe PCOS amongst adolescents, in infertile women and in mature 
women. As the title of this master thesis already has revealed, “Polycystic Ovary Syndrome - diagnosis 
and treatment” will be the main topics.
I would like to give a special thank to Professor Erik Qvigstad, for being a great supervisor and advisor, 
and for your indescribable help with accomplishing my master thesis. 
Methods:
The project method is a non-systematic literature review searching the databases UpToDate, PubMed 
and Cochrane library. The search was limited to original articles and reviews published in English. 
The search words were as following: 
- pco
- pcos
- pcos AND diagnostic
- pcos AND infertility
- pcos AND treatment
Part I: Polycystic Ovary Syndrome – Overview
The diagnosis of PCOS includes many factors that mould together to make the final diagnosis. There 
are plenty of different definitions on this syndrome depending on which region in the world you come 
from, and multiple varying mechanisms that describe the etiology behind PCOS. There are many 
divergent clinical symptoms and signs of this syndrome. Having a little background information about 
the definition, epidemiology, etiology, and the clinical presentation of the syndrome, it will help us in 
diagnosing PCOS. It is also important to differentiate PCOS from PCO. The term PCO or polycystic 
ovaries refers to the description of the ovaries as seen on the ultrasonography. Having no other 
symptoms or hormone findings, many women have ovaries that are polycystic (3). On the other hand, 
PCOS includes PCO and also other signs and symptoms, thus the name "syndrome". It is not fully 
known if PCO can develop to PCOS (3).
Definition:
Before diagnosing PCOS, it is important to make clear what definition to use for the diagnosis. As it is 
a complex syndrome, it might have different criteria as well. Stein and Leventhal were the first to 
describe PCOS, and associated amenorrhea with polycystic ovaries and sign of hirsutism (4). PCOS 
includes a majority of different features that are not otherwise explained with cutaneous signs of 
hyperandrogenism (e.g. hirsutism, acne), menstrual irregularity (e.g. oligo- or amenorrhea, or irregular 
bleeding), polycystic ovaries (one or both), obesity and insulin resistance (4).
An expert conference held in 1990 sponsored by the National Institute of Child Health and Human 
Disease (NICHD) of the United States National Institutes of Health (NIH) proposed the following 
criteria for the diagnosis of PCOS (5):
- Oligo ovulation or anovulation manifested by oligomenorrhea or amenorrhea,
- Hyperandrogenism or hyperandrogenemia
- Exclusion of other disorders that can result in menstrual irregularity and hyperandrogenism.
In 2003, the European Society for Human Reproduction and Embryology (ESHRE) and the American 
Society for Reproductive Medicine (ASRM) recommended that at least 2 of the 3 following features 
are required for PCOS to be diagnosed (6):
- Oligomenorrhea or amenorrhea
- Hyperandrogenism or hyperandrogenemia
- Polycystic ovaries on ultrasonography
In October 2013, the Endocrine Society released practice guidelines for the diagnosis of PCOS (7). 
Among their conclusions, was the recommendation of ESHRE criteria for diagnosing PCOS, with the 
presence of at least two of the following: androgen excess, ovulatory dysfunction or polycystic ovaries.
Epidemiology:  
Depending on the definition used, population and period for investigation, 5-8 % of women in fertile 
age do have PCOS according to some European studies (8). There is, however, a great deal of ethnic 
variability, especially when it comes to hirsutism and metabolic syndrome. As an example, women 
from East and Southeast Asia have less hirsutism than Caucasians given the same serum androgen 
values. In hirsute women, the incidence of acne, menstrual irregularities and polycystic ovaries are 
significantly increased (9). PCOS affects premenopausal women, and the age of onset is most often 
perimenarchal. However, in some cases the clinical recognition of the syndrome may be delayed by 
failure of the patient to become concerned by irregular menses, hirsutism or by the overlap of PCOS 
findings with normal physiologic maturation during the two years after menarche. There might be a 
genetic predisposition in women with PCOS, and the syndrome may not be unmasked before they gain 
weight (2).
Etiology:
PCOS affected women may have abnormalities in the metabolism of androgens and estrogen, while 
other affected women are genetic predisposition for the syndrome. It is questionable why the clinical 
appearances of this syndrome are so different. Being a complex syndrome of uncertain cause, there are 
many different mechanisms leading to PCOS. First of all, there are irregularities in the metabolism of 
androgens and in the control of androgen production. These patients may be encountered with high 
serum concentrations of androgenic hormones, such as testosterone and androstenedione. Nevertheless, 
a patient may have normal androgen levels, though there is considerable individual variation (10).
Hyperinsulinemia and peripheral insulin resistance are also associated with PCOS. High levels of 
insulin may augment the gonadotropin levels, thereby affecting the function of the ovaries. Insulin 
resistance can lead to metabolic and reproductive disorders. There might also be a correlation between 
hyperinsulinemia and suppression of hepatic generation of sex-hormone-binding-globulin (SHBG), 
which may increase androgenicity (11). In PCOS patients, hyperinsulinemia is responsible for 
dyslipidemia and for elevated levels of plasminogen activator inhibitors (PAI-1). Elevated levels of 
PAI-1 are a risk factor for intravascular thrombosis (11).
A suggested mechanism for high androgen levels and anovulation is that under the increased effect of 
luteinizing hormone (LH), the ovarian theca cells stimulation is also increased (12). These cells then 
increase the production of androgens.  Because of a decreased FSH ratio to LH, the granulosa cells are 
not able to aromatase the androgens to estrogens, which can lead to reduced levels of estrogen and 
anovulation (13).
Polycystic ovaries are formed when hyperandrogenemia, hyperinsulinemia and modified intraovarial 
paracrine signals together make the follicles go into arrest, causing atresia (10). This in turn causes 
irregularities in menstrual cycle, subfertility associated with anovulation, and thus follicles having a 
prolonged survival. As a consequence, an accumulation of small antralfollicles will result (10).
Part II: Polycystic Ovary Syndrome – Diagnosis
As mentioned earlier, there are many varieties in the clinical presentation of PCOS. In this section 
some of the most frequently occurring clinically manifestations are emphasized. The most used 
diagnostic criteria for PCOS are referred in the table below.
ESHRE criteria 2003
Must include two of the following:
• Anovulation or oligo-ovulation
• Clinical or biochemical signs of hyperandrogenism
• Polycystic ovaries
Clinical manifestations: 
Menstrual disorders: Abnormal menstrual cycle might be the most common symptom (14). History of 
menstrual disturbance dating back to menarche is often typical amongst patients with PCOS. 
Oligomenorrhea occurs in some women, also menstrual bleeding that occurs with intervals of 35 days 
to 6 months or amenorrhea.
Infertility is another consequence of anovulatory menstrual cycles. Higher rate of abortions amongst 
PCOS women has been observed, but the causes are not quite known (15).
Hyperandrogenism manifests clinically as excess body hair in a male distribution pattern. Typically, 
hair is seen on the upper lip, on the chin, around nipples and along linea alba of lower abdomen (16). 
The Ferriman-Gallwey score grades 11 body areas from 0 (no hair) to 4 (frankly virile), and a total 
score of 8 or more is considered abnormal for adult Caucasian women (16).
In some patients acne occurs as well. Having seborrheic skin as a PCOS patient, the chances of getting 
acne as a consequence of oil, bacteria, and dead skin cells getting trapped inside the pores of the skin 
are higher compared to normal or dry skin. In women with PCOS, androgen levels are often elevated, 
including dihydrotestosterone. This metabolite promotes oil production, which can lead to the pores 
getting clogged. Rise in oil production also manifests as greasy hair in patients with PCOS (17). 
Increased muscle mass, voice deepening and hyperandrogenism are related to more extreme forms of 
PCOS. As a differential diagnosis, symptoms of hyperandrogenism could also be consistent with 
androgen producing tumors (15).
Obesity and metabolic syndrome: Up to 80 % of women with PCOS are obese, based on waist 
circumference (18). Even though a controlled study has not been performed, one single study showed a 
43% prevalence of abdominal obesity in women with PCOS, including dyslipidemia, higher blood 
pressure and hyperinsulinemia (1). Women with PCOS should be assessed for their cardiovascular risk 
by evaluating their BMI, fasting lipid and lipoprotein levels (10).
Obstructive sleep apnea syndrome (OSAS): Obstructive sleep apnea syndrome has been observed in 
many women with PCOS, which again is a huge risk factor for cardiovascular diseases (19). Excessive 
daytime somnolence is an important question that patients should be asked about.
Hormone analyses:
Follicle stimulating hormone (FSH) level should be checked in patients with PCOS. In most cases, 
FSH levels are within the reference or even low. There are elevated levels of luteinizing hormone (LH), 
and the LH:FSH ratio is higher than 3 (13).
Measuring total and free testosterone levels are sensitive indicators of androgen excess. Levels of 
sex-hormone-binding-globulin (SHBG) are usually low in women with PCOS. Elevated levels of 
androstenedione are also common. Thyroid stimulating hormone (TSH) levels should be evaluated, 
because thyroid dysfunction can cause amenorrhea and hirsutism.
Imaging: 
Gynecologic ultrasonography, especially using a transvaginal probe, is a good screening tool for PCOS 
patients. Ultrasonography can be used to evaluate the ovarian morphology, specifically looking for 
small ovarian follicles. Bilateral enlarged ovaries with multiple small follicles are seen on ultrasound. 
The ovarian size is increased, with 12 or more follicles measuring 2-9 mm and most follicles of similar 
size. The endometrium may appear thickened, resembling that of a proliferative endometrium.  A 
transrectal approach with ultrasound is an alternative in virginal patients (18).
Serum concentrations of anti-Müllerian hormone (AMH) have been shown as a useful indicator in the 
diagnosis of PCOS.  AMH is usually at least two to three times higher in women with PCOS compared 
to normal women (15). There is a correlation between the number of small antral follicles seen on 
transvaginal ultrasonography and serum AMH concentration. A high concentration of AMH is however 
not a criteria in the diagnosis of PCOS.
If suspecting a tumor, CT or MRI methods for imaging are recommended.
Other laboratory screenings:
The diagnostic approach needs to exclude all other disorders that can result in the same clinical 
presentations as mentioned above, such as menstrual irregularities and hyperandrogenism. Cushing 
syndrome, acromegaly, adrenal and ovarian tumors and thyroid dysfunction may be some of the 
differential diagnosis (18, 19). It is therefore important to make imaging studies and laboratory 
screenings to rule out other disorders and make a clearer diagnosis.
As a screening for Cushing syndrome, a 24 hour urine sample can be used, looking for urinary free 
cortisol and creatinine levels that are at least four times the upper limit of normal (20). 
Glucose, insulin and lipids: As discussed earlier, the prevalence of glucose tolerance and type 2 
diabetes mellitus is higher in women with PCOS, and especially in patients with metabolic syndrome 
an oral glucose tolerance test should always be taken (21). Patients with PCOS that are pregnant should 
also be screened for gestational diabetes, because these women do have a higher rate of diabetes than 
the average population (19). Cholesterol levels should be measured, because in some women with 
PCOS an abnormal lipid profile is often shown (22). Insulin resistance and inflammatory markers have 
been shown to be useful in identifying adolescent girls with PCOS who have a higher risk of 
developing metabolic syndrome (23).
Part II  I:  Polycystic ovary syndrome -Treatment  
Being a syndrome, this disorder does involve various different signs and symptoms, and patients do 
come in different ages, all from adolescents to mature women. Each and every single patient has to be 
treated independently and distinct from one another. In this part, the treatment of adolescents, treatment 
of infertile women with desire of having children and the treatment of mature women will be discussed.
Diet and exercise should be considered a first line of treatment for women with PCOS, because you can 
easily reduce some of the symptoms with such simple steps. These steps include the majority of PCOS 
patients. Pharmacologic treatments are reserved for women with PCOS that also have signs and 
symptoms of hirsutism, anovulation and menstrual irregularities.
Weight loss and diet regulation reduce the risk of diabetes. Some studies have shown that this approach 
has been better than treatment with medications (18). Lifestyle modifications have been beneficial in 
restoring ovulatory cycles, improved hyperandrogenic features and in achieving pregnancy in women 
with PCOS.
PCOS patients - adolescents without infertility:
Oral contraceptives to induce regular menses and to increase sex-hormone-binding-globulin (SHBG) 
production are recommended for long term management of menstrual dysfunction (18). If hirsutism is 
not enough reduced, adding an androgen-blocking agent has been shown effective.
For patients with PCOS, the oral contraceptive of choice is called Diane. It contains estrogen 
(ethinyloestradiol) which is the most common estrogen used in nearly all the oral contraceptive pills. 
What makes Diane unique is the progesterone agent, cyproterone acetate. Cyproterone acetate is an 
anti-androgen hormone, and it therefore reduces the conversion of testosterone to its more active forms 
(24). Thereby, it reduces acne and also have a slightly effect on the abnormal hair growth. Potential side 
effects of Diane include menstrual cycle irregularity, weight gain, breast tenderness, depression and a 
slightly increased risk of thrombosis compared to other oral contraceptives (24). A thorough family 
history with no incidents of thrombosis or other coagulopathy, is in most cases enough for giving 
cyproterone acetate in Norway.  
Hirsutism can be reduced with laser treatment or electrolysis. Both reduce the amount of hair over time, 
but many treatments are required. A laser beam passes through the skin to an individual hair follicle. 
The intense heat of the laser damages the hair follicle, which inhibits future hair growth (25). In 
electrolysis, a very fine probe is inserted into the hair follicle, destroying the growth center of the hair 
with chemical or heat energy. In Norway, there is given refund of facial laser and electrolysis treatment. 
Short-term, non-pharmacologic treatments of hirsutism, such as shaving, bleaching creams and waxing 
on other body parts are not included.  
PCOS patients with infertility:
Clomiphene citrate: For a patient desiring fertility, ovulation induction can be obtained with 
clomiphene citrate (18). The mechanisms of clomiphene citrate are not fully known, but being an 
estrogen receptor antagonist, it does have the properties of interrupting the negative feedback that 
estrogen normally produces at the level of the pituitary and the hypothalamus. As a result of this, the 
follicle stimulating hormone production increases and results in follicular growth and maturation (26).
If clomiphene citrate fails, gonadotropins or laparoscopic ovarian surgery can be used to treat 
infertility (19, 28) Laparoscopic ovarian drilling is a surgical treatment that can trigger ovulation in 
women who have PCOS. A laser or diathermy is used to destroy parts of the ovaries. This treatment 
results in a dramatic lowering of male hormones within days. Many women, who fail to ovulate with 
clomiphene, will respond when these medications are reintroduced to the system after ovarian drilling.
A Norwegian gynecologist, Halvard Gjønnæss, made a long-term observational study where he 
examined late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. 
Ovarian electrocautery was performed through the laparoscope. And as a conclusion he mentioned that 
ovarian electrocautery for PCOS normalizes ovarian function, including androgen production (28).
Gonadotropin therapy is associated with an increased risk of multiple pregnancies and ovarian hyper- 
stimulation (27). Gonadotropin contains follicle stimulation hormone (FSH), luteinizing hormone (LH) 
or both. As these hormones play a central role in egg production, a PCOS patient who is not ovulating 
early in the menstrual cycle, can have daily gonadotropin injections. If this results in mature follicles, 
the ovary is ready to ovulate (26).
In vitro fertilization (IVF) is reserved for PCOS women with unsuccessful gonadotropin therapy. This 
is a therapy where an egg is fertilized by sperm outside the body, and then is the fertilized egg 
reinserted into the uterus. 
PCOS patients - mature women:
In mature women with PCOS, the treatment has to reduce long term complications such as diabetes 
mellitus type 2, metabolic syndrome and cardiovascular diseases. Diet and exercise are considered as 
first line treatment, especially in mature women.
Metformin, an oral anti hyperglycemic drug, is considered as a treatment in patients with type 2 
diabetes mellitus. It is also considered in patients with PCOS who are insulin resistant. The American 
College of Obstetricians and Gynecologists recommends a fasting glucose level and a two hour glucose 
level after a 75 g glucose load as a screening for type 2 diabetes in women with PCOS (18). Around 7, 
5% of women with PCOS have type 2 diabetes mellitus according to WHO based on an oral glucose 
tolerance test (15). Clinically, it has been shown that metformin effectively decreases androgen levels, 
as well as improving insulin sensitivity and facilitates weight loss in patients with PCOS as early as 
adolescents (29, 30). The main function of metformin is to reduce the level of insulin. Metformin also 
affects the proliferation of theca cells and endometrial growth, inhibits the ovarian gluconeogenesis and 
contributes to reduced androgen production (26).
Metabolic syndrome in women is characterized by abdominal obesity with waist circumference >35 
inch, dyslipidemia with triglyceride level >150 mg/dL, high density lipoprotein cholesterol level <50 
mg/dL and elevated blood pressure (1). This syndrome will lead to increased risk of coronary artery 
calcification and atherosclerosis.  Some patients with PCOS have to be treated with statins to reduce 
the risk of cardiovascular diseases. High blood pressure has to be treated with antihypertensives, if 
loosing weight, regular exercise and eating healthy does not help reducing it. 
Overview of treatment options in PCOS patients.
Adolescents: Infertile women: Mature women:
- Diet and weight regulation
- Oral contraceptives.           
With acne: add anti-androgen
- Laser or electrolysis for 
hirsutism
- Diet and weight 
regulation
- Clomiphene citrate
- Gonadotropins or 
laparoscopic drilling
- In vitro fertilization
- Diet and weight regulation
- Metformin
- Antihypertensives and/or 
statins
5. Conclusion
There are many various definitions of polycystic ovary syndrome, but in most cases they include 
irregularities in the menstrual cycle, anovulation, hyperandrogenism, hirsutism and acne (14). The 
Endocrine Society released practice guidelines in 2013 using the Rotterdam criteria for diagnosing 
PCOS with the presence of two of the following: androgen excess, ovulatory dysfunction or polycystic 
ovaries (9). The exact pathogenesis in PCOS is unknown, even though there are many studies that 
conclude that hyperinsulinemia does play a major role (11).
Lifestyle modifications have a positive impact on the risk reduction for diabetes, as well as in restoring 
ovulatory cycles, improved hyperandrogenic features and in achieving pregnancy in women with 
PCOS (18). Diet regulation and weight loss are considered as a first line treatment.
As it is a complex syndrome and there is a variety in symptoms and signs in individuals with PCOS, 
the treatment must be adapted according to the individual’s age, weight and insulin resistance. It should 
be considered as a goal, reducing the signs and symptoms of hyperandrogenism, insulin resistance and 
to recreate a normal menstrual cycle and ovulation with drug treatment in PCOS patients.
It is also necessary for those who are treating patients with PCOS to inform them about long term 
complications associated with this syndrome, such as infertility, diabetes, metabolic syndrome and 
cardiovascular diseases.
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